lncSNHG3 drives breast cancer progression by epigenetically increasing CSNK2A1 expression level
Related Experiment Video
Updated: Jul 26, 2025

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
Zhenlin Nie1, Mu Xu1, Linpeng Zhou2
1Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China.
Abstract:
Mounting evidence demonstrates that long noncoding RNAs (lncRNAs) have critical roles in the initiation and progression of cancer. Here, we report that small nucleolar RNA host gene 3 (SNHG3) is a key regulator of breast cancer progression. We analyzed RNA sequencing data to explore abnormally expressed lncRNAs in breast cancer. The effects of SNHG3 on breast cancer were investigated via in vitro and in vivo assays (CCK-8 assay, colony formation assay, flow cytometry assay, EdU assay, xenograft model, immunohistochemistry, and Western blot). The mechanism of SNHG3 action was explored through bioinformatics, RNA fluorescence in situ hybridization, luciferase reporter assay, RNA pull-down assay, chromatin immunoprecipitation assay and RNA immunoprecipitation assay. We found that SNHG3 expression was upregulated in breast cancer tissues and that its high expression level was associated with poor survival. We also found that high SNHG3 expression was partly induced by STAT3. Moreover, SNHG3 knockdown significantly repressed breast cancer cell growth both in vitro and in vivo. In the cytoplasm, SNHG3 facilitated the expression of Casein kinase II-A1 (CSNK2A1) by absorbing miR-485-5p and recruiting the HuR protein, participating in the malignant progression of breast cancer. Taken together, our study reveals a SNHG3-based regulatory network, which plays an oncogenic role in breast cancer and suggests that SNHG3 may serve as a potential target for the diagnosis and treatment of breast cancer.
Insights
Small nucleolar RNA host gene 3 (SNHG3) drives breast cancer progression by regulating CSNK2A1. Inhibiting SNHG3 suppressed tumor growth, suggesting it as a potential diagnostic and therapeutic target for breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
- Aberrant expression of lncRNAs contributes to the initiation and progression of various cancers, including breast cancer.
Purpose of the Study:
- To investigate the role of small nucleolar RNA host gene 3 (SNHG3) in breast cancer progression.
- To elucidate the underlying molecular mechanisms by which SNHG3 influences breast cancer malignancy.
Main Methods:
- Analysis of RNA sequencing data from breast cancer tissues.
- In vitro and in vivo experiments including cell proliferation, apoptosis, and xenograft assays.
- Mechanistic studies involving bioinformatics, RNA fluorescence in situ hybridization, luciferase reporter assays, and RNA immunoprecipitation.
Main Results:
- SNHG3 expression was significantly upregulated in breast cancer tissues and correlated with poor patient survival.
- SNHG3 knockdown inhibited breast cancer cell proliferation and tumor growth in vitro and in vivo.
- SNHG3 was found to promote breast cancer progression by sponging miR-485-5p and upregulating Casein kinase II-A1 (CSNK2A1) expression in the cytoplasm.
Conclusions:
- SNHG3 acts as an oncogene in breast cancer, promoting malignant progression through the SNHG3/miR-485-5p/CSNK2A1 axis.
- SNHG3 represents a potential biomarker for breast cancer diagnosis and a promising therapeutic target.
More Related Videos
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
Related Concept Videos
Epigenetic Regulation
lncRNA - Long Non-coding RNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...